Radiofrequency ablation for Barrett's esophagus

Area of Science:

• Gastroenterology
• Oncology
• Endoscopic Therapeutics

Background:

• Barrett's esophagus is a precancerous condition.
• Dysplasia and early esophageal adenocarcinoma (EAC) require effective management.
• Radiofrequency ablation (RFA) is a key therapeutic option.

Purpose of the Study:

• To review recent evidence on radiofrequency ablation (RFA) for Barrett's esophagus.
• To assess the efficacy, durability, and safety of RFA.
• To highlight recent advancements in RFA techniques and patient selection.

Main Methods:

• Review of studies published within the last year.
• Analysis of data on RFA efficacy, durability, and safety.
• Evaluation of disease recurrence and progression rates.

Main Results:

• Radiofrequency ablation (RFA) is generally well-tolerated and effective for most patients with Barrett's esophagus, dysplasia, and early esophageal adenocarcinoma (EAC).
• Recent reports indicate variable rates of disease recurrence after RFA.
• Disease progression can occur in a small subset of patients, even after complete eradication.

Conclusions:

• Endoscopic mucosal resection and RFA are foundational treatments for dysplasia and early EAC in Barrett's esophagus.
• Despite RFA's demonstrated effectiveness and safety, disease recurrence and progression persist as challenges in a subset of patients.
• Ongoing research aims to identify predictors of response and recurrence to optimize RFA therapy.